The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma

On June 24, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lisocabtagene maraleucel (liso-cel, Breyanzi), a chimeric antigen receptor (CAR) T cell therapy, for adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. It is not indicated for the treatment of patients with primary central nervous system lymphoma.

“DLBCL is the most common type of lymphoma, and while our investment in research has improved outcomes for many, patients with relapsed or refractory disease face important decisions for second-line therapy,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “Lisocabtagene maraleucel is an innovative treatment that offers a new option for these patients, and another reason for this community to maintain hope for the future.”

For more information on the FDA approval of lisocabtagene maraleucel (BREYANZI), visit the FDA’s website.  To learn more about treatment options for DLBCL visit the DLBCL Learning Centers.